Article
FDA Designates Intellia's Nexiguran Ziclumeran (Nex-z) As A Regenerative Medicine Advanced Therapy
On November 25, 2024, Intellia Therapeutics announced that its CRISPR-based therapy, nexiguran ziclumeran...
Goodwin Procter LLP
Use advanced search filters to refine your search
